Clinical trials: Neoplasms, Liver
Hepatocarcinoma, Cholangiocarcinoma
Study on the Quality of Life (QoL) After Liver Surgery
Liver cancer in adult men is the fifth most frequently diagnosed cancer worldwide, and is the second leading cause of cancer-related death in the world.
- Conditions
- Hepatocarcinoma, Cholangiocarcinoma, Quality of Life
- Trial name
- NCT05464706
- Testing
- Synchrolevels
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Humanitas Clinical and Research Center
Colorectal Cancer
Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.
- Trial name
- NCT00874406
- Testing
- tac + folfox4, folfox4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular, Neoplasms, Liver
Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma
The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of small hepatocellular carcinoma in patients with cirrhosis.
- Trial name
- NCT01096914
- Testing
- percutaneous radiofrequency ablation, percutaneous laser ablation
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Cardarelli Hospital
Hepatocellular Carcinoma
HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma
Overall, although there are many options for second-line treatment of liver cancer, the ORR is mostly limited to within 20-30%, with a median PFS of 3-5 months and a median OS of 10-20 months.
- Trial name
- NCT06475287
- Testing
- HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Hepatic Carcinoma
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.
- Trial name
- NCT01760616
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 790 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Liver Neoplasms
Multimodal Ultrasound and Focal Liver Lesions (FLLs)
Background and aim: FLLs are common findings in abdominal ultrasound and differential diagnosis between benign and malignant lesions is often challenging, especially in patients with chronic liver diseases.
- Trial name
- NCT05977764
- Testing
- Ultrasound
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma (HCC)
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had…
- Trial name
- NCT07709299
- Testing
- Autologous Cytokine-Induced Killer (CIK) Cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Hepatocellular Carcinoma
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
TACE is considered the standard treatment for unresectable HCC and is widely used as a palliative treatment. However there is no consensus of the protocol of TACE.One of the variation is does the stability of the suspension by…
- Trial name
- NCT01259414
- Testing
- Solvent with specific gravity less than lipiodol, Solvent with specific gravity equivalent to lipiodol
- Where
- China
- Volunteers
- 812 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife Position
Since the first report of laparoscopic resection of a benign hepatic tumor by Professor H. Reith in 1991, the laparoscope has been widely used in liver disease.
- Trial name
- NCT02809287
- Testing
- Jackknife posture
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
This is an open, single-arm clinical study to observe and evaluate the efficacy and safety of first-line treatment of patients with stage C hepatocellular carcinoma of BCLC at HAIC in combination with adebrelimab and apatinib.
- Trial name
- NCT06482008
- Testing
- Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms, Neoplasm Metastasis
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
In this study, the investigators assessed the effect of Cetuximab in combination with chemotherapy in the treatment of unresectable metastatic colorectal cancer.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms
- Trial name
- NCT01564810
- Testing
- Cetuximab, chemotherapy of mFOLFOX6 or FOLFIRI
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xu jianmin
Hepatocellular Carcinoma
Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion
The purpose of this study is to compare the effects of different multimodality therapy strategies (initial hepatectomy followed by transcatheter hepatic arterial chemoembolization and/or local regional treatments compare with…
- Trial name
- MDTforHCC (NCT00501813)
- Testing
- Hepatectomy, TACE combined with local regional therapies without hepatectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
This is a pilot study with a single arm in a single center assessing safety and efficacy of combination therapy of TACE and ablation and durvalumab.
- Trial name
- NCT04517227
- Testing
- Durvalumab, Transcatheter Hepatic Arterial Chemoembolization (TACE), Ablation
- Volunteers
- 30 people
- Sponsor
- Fudan University
Pancreatic Cancer, Liver Cancer
Ultrasound Monitoring of Abdominal Soft Tissue
This research study is being done to collect data and analyze the motion of soft tissue in the abdomen (liver, pancreas, stomach and intestines) of people who have pancreatic and liver cancer as well as healthy volunteers.
- Trial name
- NCT02722616
- Testing
- Ultrasound scan of the pancreas, Ultrasound scan of the Liver, Reference ultrasound
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma
Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma
The PRIME-HCC trial will assess the effects of combination treatment with nivolumab (OPDIVO) and ipilimumab (YERVOY) pre-operatively in hepatocellular carcinoma patients for whom liver resection is planned.
- Trial name
- PRIME-HCC (NCT03682276)
- Testing
- Ipilimumab, Nivolumab
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Imperial College London
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00454376
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 408 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Rhabdomyosarcoma
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma
- Trial name
- NCT04715191
- Testing
- CARE T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine